Trials / Not Yet Recruiting
Not Yet RecruitingNCT07438444
A Study of Tirzepatide (LY3298176) in Adult Participants in India With Either Type 2 Diabetes Mellitus or Obesity
A Phase 4, Open-Label, Single-Arm, 46-Week Study to Investigate the Safety and Efficacy With Tirzepatide in Adult Indian Participants With Either Type 2 Diabetes or Obesity
- Status
- Not Yet Recruiting
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 344 (estimated)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to measure the safety and efficacy of tirzepatide in adult participants in India who have type 2 diabetes or who have obesity or overweight without type 2 diabetes. Participation in the study will last about 46 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tirzepatide | Administered SC |
Timeline
- Start date
- 2026-03-01
- Primary completion
- 2027-10-01
- Completion
- 2027-10-01
- First posted
- 2026-02-27
- Last updated
- 2026-02-27
Locations
21 sites across 1 country: India
Source: ClinicalTrials.gov record NCT07438444. Inclusion in this directory is not an endorsement.